Accordingly, genetic DDAH deletion leads to enhanced hypoxic vasoconstriction and pulmonary hypertension [14], whilst DDAH overexpression attenuates the sustained phase of hypoxic pulmonary vasoconstriction [15]. The gene discussed is DDAH1; the disease is pulmonary arterial hypertension.